πŸ‡ΊπŸ‡Έ FDA
Patent

US 12208099

Combination therapies

granted A61KA61K31/428A61K31/4375

Quick answer

US patent 12208099 (Combination therapies) held by Mirati Therapeutics, Inc. expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Mirati Therapeutics, Inc.
Grant date
Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/428, A61K31/4375, A61K31/44, A61K31/4985